Covance Inc.
announced its genomics laboratory, located in Seattle, Washington, has received Clinical Laboratory Improvement Amendment (CLIA) certification from the State of Washington Department of Health. The laboratory received its license from the State of Washington in May 2010, and completed the initial CLIA inspection, with no findings, in December 2010.
In addition to performing CLIA-regulated services, Covance’s genomics laboratory has tailored its standards to meet GLP requirements. The laboratory has performed multiple GLP protocols and undergone subsequent GLP audits from pharmaceutical-based clients.
Covance Genomics Laboratory, acquired in August 2009 from Merck, recently celebrated 10 years of supporting drug discovery and development work since its inception as part of Rosetta Inpharmatics. The laboratory is purpose-built to support genomics-based drug development with services including: next generation sequencing, gene expression profiling, genome-wide genotyping, qPCR biomarker assays, microRNA profiling, targeted genotyping, tissue homogenization and nucleic acid extraction, scalable amplification protocols, and computational biology & bioinformatics. Having run more than 450,000 samples to date, the laboratory provides end-to-end services for genomics-based drug development research.
Mandated by the Code of Federal Regulations (CFR 42 Part 493.2), the Centers for Medicare & Medicaid Services (CMS) manage and conduct inspections of CLIA laboratories. The regulation was enacted to ensure consistent, accurate, and reliable clinical test result reporting from laboratories across the country used for the diagnosis, treatment, and/or prognosis of disease in human subjects. CLIA applies to all clinical laboratories operating in the United States and its territories and encompasses more than 200,000 clinical testing sites; the State of Washington is one of four exempt states and manages CLIA laboratories within Washington.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.